Dermatol Ther 2017 May 17;30(3). Epub 2017 Feb 17.
Department of Dermatology, Baylor Scott & White Health, Texas A&M Health Science Center College of Medicine, Temple, Texas, 76508.
Vemurafenib is a selected BRAF kinase inhibitor approved for treating metastatic or unresectable melanoma, which has numerous cutaneous side effects unfortunately, including three previously reported cases of asymptomatic areola and/or nipple hyperkeratosis. We present the first case of painful bilateral nipple hyperkeratosis secondary to vemurafenib in an 84-year-old woman. She was successfully treated with tretinoin 0. Read More